Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 24, 2026 | June 26, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | EVP, Chief Financial Officer | August 23, 2021 | August 25, 2021 |
| ViewRay, Inc.VRAY · Entity 111118 | Chief Financial Officer | March 01, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,392 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 4,392 · Balance 4,392 F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
HAEMONETICS CORP
Report date August 23, 2021 · Filed August 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,291 |
Last balance in matching sequence
After 2021-08-23 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-08-23 · Exercise / conversion · Acquired 11,232 · Balance 41,523 F3: This number includes unvested RSUs previously reported. Row 2 · 2021-08-23 · Exercise / conversion · Acquired 11,435 · Balance 52,958 F3: This number includes unvested RSUs previously reported. Row 3 · 2021-08-23 · Sale · Disposed 22,667 · Balance 30,291 F1: Transaction pursuant to an existing 10b5-1 trading plan. F2: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: This number includes unvested RSUs previously reported. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.21 · Expires 2023-10-25 | Direct | 0 |
Reported balance
After 2021-08-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-23 · Exercise / conversion · Disposed 11,232 · Balance 0 F1: Transaction pursuant to an existing 10b5-1 trading plan. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.64 · Expires 2024-06-06 | Direct | 0 |
Reported balance
After 2021-08-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-23 · Exercise / conversion · Disposed 11,435 · Balance 0 F1: Transaction pursuant to an existing 10b5-1 trading plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to an existing 10b5-1 trading plan.
F2: Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $60.06 to $60.88, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: This number includes unvested RSUs previously reported.
ViewRay, Inc.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 356,318 |
Reported balance
After 2023-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 103,686 · Balance 356,318 F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. A total of one-third of the shares subject to this grant become vested on each of the first three anniversaries of March 1, 2023, subject to the Reporting Person remaining a service provider through each such vesting date. F2: Includes 356,318 shares granted as RSUs. As of the transaction date, zero RSUs have vested. |
| Performance UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 103,686 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 103,686 · Balance 103,686 F3: These performance share awards were issued at a 100% target and have a 3-year vest period and will vest in all or in part upon achievement of performance metrics. Any awards that have not been vested and released at the end of the 3-year period will be cancelled. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. A total of one-third of the shares subject to this grant become vested on each of the first three anniversaries of March 1, 2023, subject to the Reporting Person remaining a service provider through each such vesting date.
F2: Includes 356,318 shares granted as RSUs. As of the transaction date, zero RSUs have vested.
F3: These performance share awards were issued at a 100% target and have a 3-year vest period and will vest in all or in part upon achievement of performance metrics. Any awards that have not been vested and released at the end of the 3-year period will be cancelled.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,413 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 66,943 · Balance 67,413 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 67,413 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2018 Filed Oct 30, 2018 21:18 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 779 | $101.69 | $79,216.51 |
DisclosureSEC source: 0001127602-18-031291 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,825 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 5,717 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · derivative · entry 4 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 5,717 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 970 | $92.17 | $89,404.90 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · nonDerivative · entry 3 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,604 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 5,717 | $92.17 | $526,935.89 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · nonDerivative · entry 2 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,574 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 21:14 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 5,717 | $41.64 | $238,055.88 |
DisclosureSEC source: 0001127602-18-021961 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,278 | $0.00 Strike: $93.52 | $0.00 |
DisclosureSEC source: 0001127602-18-020833 · form4.xml · derivative · entry 2 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,278 Underlying: Common Stock · 9,278 shares Expires 2025-06-11 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 23:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,606 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-020833 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,574 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:40 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 425 | $92.73 | $39,410.25 |
DisclosureSEC source: 0001127602-18-020488 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,968 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,231 | $0.00 Strike: $34.21 | $0.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · derivative · entry 20 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,695 Underlying: Common Stock · 11,231 shares Expires 2023-10-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 162 | $54.34 | $8,803.08 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 19 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,034 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.33 | $5,433.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 18 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,196 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $54.31 | $10,862.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 17 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,296 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $54.29 | $10,858.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 16 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,496 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.28 | $5,428.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 15 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,696 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.23 | $5,423.30 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 14 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,796 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 161 | $54.21 | $8,727.81 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 13 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,896 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 39 | $54.20 | $2,113.80 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 12 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,057 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.19 | $5,419.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 11 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,096 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.17 | $5,417.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 10 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,196 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.16 | $5,416.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 9 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,296 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $54.15 | $10,830.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 8 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,396 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $54.29 | $10,858.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 7 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,596 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 200 | $54.10 | $10,820.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 6 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,796 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.04 | $5,404.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 5 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,996 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 100 | $54.03 | $5,403.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 4 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,096 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,122 | $54.01 | $60,599.22 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 3 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,196 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 9,909 | $54.00 | $535,086.00 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 2 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,318 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 11,231 | $34.21 | $384,212.51 |
DisclosureSEC source: 0001127602-17-032439 · form4.xml · nonDerivative · entry 1 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2017 Filed May 23, 2018 21:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 841 | $46.76 | $39,325.16 |
DisclosureSEC source: 0001127602-18-018566 · form4.xml · nonDerivative · entry 1 Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,393 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 22,870 | $41.64 Strike: $41.64 | $952,306.80 |
DisclosureSEC source: 0001127602-17-020971 · form4.xml · derivative · entry 2 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,870 Underlying: Common Stock · 22,870 shares Expires 2024-06-06 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 5,583 | $41.64 | $232,476.12 |
DisclosureSEC source: 0001127602-17-020971 · form4.xml · nonDerivative · entry 1 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,996 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 22:44 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantPerformance Shares · Derivative | 20,827 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-065405 · form4.xml · derivative · entry 3 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,827 Underlying: Common Stock · 20,827 shares Expires 2019-12-31 F3 · derivative.exercise_date: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d). Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 22:44 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 44,926 | $34.21 Strike: $34.21 | $1,536,918.46 |
DisclosureSEC source: 0001127602-16-065405 · form4.xml · derivative · entry 2 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,926 Underlying: Common Stock · 44,926 shares Expires 2023-10-25 F2 · derivative.exercise_date: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 22:44 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 10,413 | $34.21 | $356,228.73 |
DisclosureSEC source: 0001127602-16-065405 · form4.xml · nonDerivative · entry 1 Burke Willaim P · CIK 0001682069 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,413 F1 · shares: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.